Company: INMB
Filing Date: 2025-06-30
Form Type: 424B5
Source: 0001213900-25-059298
Chunk: 3

Company: Inmune Bio, Inc.
Filing Date: 2025-06-30
Form: 424B5
Chunk 3
---
 documents to which we
have referred you in the sections of this prospectus titled “Where You Can Find Additional Information” and “Incorporation
of Information by Reference”.

Unless otherwise indicated,
all information contained or incorporated by reference in this prospectus supplement and the accompanying prospectus concerning our industry
in general or any portion thereof, including information regarding our general expectations and market opportunity, is based on management’s
estimates using internal data, data from industry related publications, consumer research and marketing studies and other externally obtained
data.

In this prospectus supplement
and the accompanying prospectus, unless the context otherwise requires, references to “INmune Bio,” the “Company,”
“we,” “our,” or “us,” refer to INmune Bio Inc. and its wholly-owned subsidiaries, unless the context
suggests otherwise. When we refer to “you”, we mean the potential holders of our securities. Capitalized terms used, but not
defined, in this prospectus supplement are defined in the accompanying prospectus.

<div align='center'>S-ii

PROSPECTUS SUPPLEMENT SUMMARY</div>

This summary highlights certain information about this offering and selected information contained or incorporated by reference into this prospectus supplement and the accompanying prospectus. This summary is not complete and does not contain all of the information that you should consider before deciding whether to invest in our common stock. You should carefully read this entire prospectus supplement and accompanying prospectus, including the information incorporated herein and therein, including the “Risk Factors” section beginning on page S-4 of this prospectus supplement and the other documents incorporated by reference into this prospectus supplement, before making an investment decision.

Our objective is to develop
and commercialize our product candidates to treat diseases where the innate immune system is dysfunctional causing or contributing to
the patient’s disease. Innate immune dysfunction can occur for a variety of reasons including genetics, lifestyle, and other factors.
However, age plays a significant role in the development of immune dysfunction. Innate immune dysfunction can be seen in cancer where
Natural Killer (“NK”) cells are impaired and facilitate a tumor’s evasion of the immune system and subsequent disease
progression. Chronic inflammation is implicated in neurologic and metabolic diseases where it impairs the innate immune system. Our primary
focus continues to be treatment of cancer with INKmune and treatment of Alzheimer’s Disease (“AD”) and Treatment Resistant
Depression (“TRD”) with XPro1595 (“XPro”). We have added CORD